Projecting the Effectiveness of RotaTeq® Against Rotavirus-Related Hospitalizations and Deaths in Six Asian Countries

This article, published in Human Vaccines, describes the projected effectiveness of RotaTeq®, which is an oral pentavalent rotavirus vaccine (RV5), against rotavirus gastroenteritis (RGE)-related hospitalizations and deaths in six Asian countries based on a simple mathematical model. The model projected an overall effectiveness in the region of 82 to 89 percent against RGE-related hospitalizations and a substantial reduction in RGE-related deaths, suggesting that RV5 could substantially reduce the burden of rotavirus disease in Asia.

Author(s): El Khoury AC, Mast TC, Ciarlet M, Markson LE, Goveia MG

Published: 2011

  • Download file (English)

    310 KB PDF (Located at www.landesbioscience.com)

    Citation: El Khoury AC, Mast TC, Ciarlet M, Markson LE, Goveia MG. Projecting the Effectiveness of RotaTeq® Against Rotavirus-Related Hospitalizations and Deaths in Six Asian Countries. Human Vaccines. 2011;7(5):506-510.